Zai Lab Limited (NASDAQ:ZLAB) Insider Frazor Titus Edmondson III Sells 4,369 Shares

Zai Lab Limited (NASDAQ:ZLAB) insider Frazor Titus Edmondson III sold 4,369 shares of the firm’s stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $35.89, for a total value of $156,803.41. Following the transaction, the insider now directly owns 27,217 shares of the company’s stock, valued at $976,818.13. This represents a 13.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Frazor Titus Edmondson III also recently made the following trade(s):

• On Friday, February 28th, Frazor Titus Edmondson III sold 14,544 shares of Zai Lab stock. The shares were sold at an average price of $32.98, for a total transaction of $479,661.12.

Zai Lab Trading Down 13.4 %

NASDAQ:ZLAB opened at $31.77 on Friday. The business’s fifty day moving average price is $32.72 and its 200 day moving average price is $28.77. The firm has a market capitalization of $3.48 billion, a price-to-earnings ratio of -11.47 and a beta of 1.07. Zai Lab Limited has a 1-year low of $13.48 and a 1-year high of $39.77.

Zai Lab (NASDAQ:ZLAB) last issued its earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.19). The business had revenue of $109.07 million during the quarter, compared to analyst estimates of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. Equities analysts forecast that Zai Lab Limited will post -2.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ZLAB shares. Scotiabank assumed coverage on shares of Zai Lab in a research note on Friday, March 7th. They set a “sector outperform” rating and a $55.00 target price for the company. Bank of America reiterated a “neutral” rating and set a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. JPMorgan Chase & Co. lifted their target price on Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, March 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a report on Thursday, March 27th.

Hedge Funds Weigh In On Zai Lab

A number of hedge funds have recently modified their holdings of ZLAB. GF Fund Management CO. LTD. acquired a new stake in Zai Lab during the fourth quarter valued at $29,000. Public Employees Retirement System of Ohio lifted its holdings in shares of Zai Lab by 20.8% during the 4th quarter. Public Employees Retirement System of Ohio now owns 18,480 shares of the company’s stock valued at $484,000 after buying an additional 3,179 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Zai Lab by 2.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company’s stock valued at $1,496,000 after buying an additional 1,200 shares in the last quarter. Woodline Partners LP increased its holdings in Zai Lab by 9.4% in the fourth quarter. Woodline Partners LP now owns 1,759,797 shares of the company’s stock worth $46,089,000 after buying an additional 151,835 shares during the last quarter. Finally, Vestal Point Capital LP bought a new position in Zai Lab during the fourth quarter valued at approximately $7,857,000. 41.65% of the stock is owned by institutional investors and hedge funds.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.